

# [<sup>125</sup>I]-SAR<sup>1</sup>-ILE<sup>8</sup>-ANGIOTENSIN II

Product Number: NEX248

Sar-Arg-Val-[<sup>125</sup>I]Tyr-Ile-His-Pro-Ile

## LOT SPECIFIC INFORMATION

<b>CALCULATED AS OF:</b>			11-Aug-2025	<b>Package Size Information</b>	
<b>LOT NUMBER:</b>			EJ91250	<b>Package Size</b>	
<b>SPECIFIC ACTIVITY</b>			81.4 TBq/mmol	<b>as of</b>	
			2200 Ci/mmol	<b>12-Sep-2025</b>	
			68.3 MBq/μg	<b>370 kBq</b>	
			1846 μCi/μg	<b>10 μCi</b>	
				<b>1.85 MBq</b>	
				<b>50 μCi</b>	

**RADIOCHEMICAL PURITY:** ≥ 95%

**MOLECULAR WEIGHT:** ~1192

**PACKAGING:** [<sup>125</sup>I]-Sar<sup>1</sup>-Ile<sup>8</sup>-Angiotensin II is lyophilized from 0.04M sodium phosphate buffer, pH 4.6, containing 1M glycine, 0.18M sodium chloride and 0.25% BSA. It is shipped ambient.

**STABILITY AND STORAGE:** The lyophilized [<sup>125</sup>I]-Sar<sup>1</sup>-Ile<sup>8</sup>-Angiotensin II should be stored at 4°C or lower. Following reconstitution with distilled water to a concentration of approximately 50 µCi/ml on calibration date, aliquot and store at -20°C or lower. Under these conditions the product is stable and usable for at least eight weeks after fresh lot date.

**SPECIFIC ACTIVITY:** The initial specific activity of [<sup>125</sup>I]-Sar<sup>1</sup>-Ile<sup>8</sup>-Angiotensin II is 2200 Ci/mmol (81 TBq/mmol), 1846 µCi/µg (68.3 MBq/µg). Preparative HPLC is used to separate unlabeled Sar<sup>1</sup>-Ile<sup>8</sup>-Angiotensin II from [<sup>125</sup>I]-Sar<sup>1</sup>-Ile<sup>8</sup>-Angiotensin II. Upon decay, [<sup>125</sup>I]-Sar<sup>1</sup>-Ile<sup>8</sup>-Angiotensin II undergoes decay catastrophe and the specific activity remains constant with time. However, it is not known what molecular fragments are generated from the decay event or what functional activity these fragments may have in different assays. References on <sup>125</sup>I decay and decay catastrophe of <sup>125</sup>I labeled compounds are available.<sup>1-5</sup>

**RADIOCHEMICAL PURITY:** Initially greater than 95% radiochemically pure as determined by HPLC.

**PREPARATIVE PROCEDURE:** Sar<sup>1</sup>-Ile<sup>8</sup>-Angiotensin II is radioiodinated with no carrier added <sup>125</sup>I using a modification of the Hunter and Greenwood method<sup>6</sup> and purified by reversed phase HPLC.

**AVAILABILITY:** [<sup>125</sup>I]-Sar<sup>1</sup>-Ile<sup>8</sup>-Angiotensin II is routinely available from stock. It is prepared fresh and packaged for shipment on the second Monday of each month. Please inquire for larger package sizes.

**APPLICATIONS:** [<sup>125</sup>I]-Sar<sup>1</sup>-Ile<sup>8</sup>-Angiotensin II is an angiotensin receptor antagonist<sup>7</sup> which binds to a single class of receptors.<sup>8,9</sup> [<sup>125</sup>I]-Sar<sup>1</sup>-Ile<sup>8</sup>-Angiotensin II is useful for studying AT<sub>1</sub> receptors when an antagonist ligand is preferred, for receptor localization studies using autoradiographic techniques<sup>10,11</sup> and for drug screening programs.

**HAZARD WARNING:** This product contains a chemical (s) known to the state of California to cause cancer. This product also contains a component which is harmful by contact, ingestion and inhalation. It is irritating to the eyes, skin and respiratory tract and is toxic.

eyes, skin and respiratory tract and is toxic.

**RADIATION UNSHIELDED:** 280mR/hr/mCi at vial surface.

## REFERENCES:

- 1 Doyle, V.M., Buhler, F.R. and Burgisser, E., *Eur. J. Pharm* 99 353 (1984).
- 2 Schmidt, J., *J. Biol. Chem.* 259 1160 (1984).
- 3 Loring, R.H., Jones, S.W., Matthews-Bellinger, J. and Salpeter, M.M., *J. Biol. Chem.* 257 1418 (1982).
- 4 Berridge, M.S., Jiang, V.W. and Welch, M.J., *Rad. Res.* 82 467 (1980).
- 5 Charlton, D.E., *Rad. Res.* 107 163 (1986).
- 6 Hunter, W.M. and Greenwood F.C., *Nature* 194 495 (1962).
- 7 Khosla, M.C (1972).
- 8 Speth, R.C., Singh, R., Smeby, R.R., Ferrario, C.M. and Husain, A. *Neuroendocrinology* 38 387 (1984).
- 9 Husain, A., Bumpus, F.M., Desilva, P., and Speth, R.C. *Proc. Natl. Acad. Sci. U.S.A.* 84 2489 (1987).
- 10 McKinley, M.J., Allen, A., Clevers, J., Denton, D.A., and Mendelsohn, F.A.O. *Brain Res.* 375 373 (1986).
- 11 Millan, M., Aguilera, G., Wynn, P.C., Mendelsohn, F.A.O. and Catt, K.J. *Methods Enz.* 124 590 (1986).

## IODINE-125 DECAY CHART HALF LIFE=60 days

**Radiations:** Gamma 35.5 keV (7%) , X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

DAYS	0	2	4	6	8	10	12	14	16	18
0	1.000	0.977	0.955	0.933	0.912	0.891	0.871	0.851	0.831	0.812
20	0.794	0.776	0.758	0.741	0.724	0.707	0.691	0.675	0.660	0.645
40	0.630	0.616	0.602	0.588	0.574	0.561	0.548	0.536	0.524	0.512
60	0.500	0.489	0.477	0.467	0.456	0.445	0.435	0.425	0.416	0.406
80	0.397	0.388	0.379	0.370	0.362	0.354	0.345	0.338	0.330	0.322
100	0.315	0.308	0.301	0.294	0.287	0.281	0.274	0.268	0.262	0.256
120	0.250	0.244	0.239	0.233	0.228	0.223	0.218	0.213	0.208	0.203

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

revvity

Revvity, Inc.  
940 Winter Street  
Waltham, MA 02451 USA

(800) 762-4000  
www.revvity.com

For a complete listing of our global offices, visit [www.revvity.com](http://www.revvity.com)  
Copyright © 2023, Revvity, Inc. All rights reserved.